Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (OPTION TREAT)

Inclusion Criteria: Both genders aged 18 years or older; Currently on dual antihypertensive therapy for at least 8 weeks, and non responders to that treatment, defined as measurements of SBP ≥ 140 mmHg and ≤180 mmHg and/or DBP≥90mmHg and ≤110 mmHg, assessed at the screening visit and randomization visit (both conditions are in accordance with the Brazilian Hypertension Guideline - 2020); Able to understand and consent to their participation in this clinical trial, manifested by signing the Informed Consent Form; Exclusion Criteria: Any significant clinical condition that, in the investigator's opinion, may interfere with participant safety; Any laboratory test finding that, in the investigator's opinion, may interfere with participant safety; Suspected or diagnosed with COVID 19; History of hypersensitivity to components of drugs used during the trial or to drugs derived from sulfonamides; Pregnant or breastfeeding women; Women in a reproductive age who do not agree to use contraceptive methods; Male participants who do not agree to use contraceptive methods; Participation in clinical trial protocols in the last 12 (twelve) months, unless the investigator judges that there may be a direct benefit to the participant; Participant who has some kind of relationship up to the second degree or bond with collaborators or employees of the Sponsor and the Research site; Estimated glomerular filtration rate (eGFR) less than 45 ml/min /1.73m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) or end-stage renal disease; Severe liver dysfunction; Cardiogenic shock or reduced ejection fraction heart failure with a left ventricular ejection fraction less than or equal to 50%; Symptomatic congestive heart failure class II, III or IV, according to the New York Heart Association and/or participants with a history of infarction, unstable angina or cerebrovascular accident in the last 6 months prior to the beginning of the study; Clinically relevant ventricular cardiac arrhythmias; Obstructive coronary artery disease; Dementia syndrome; History of alcohol or illicit drug addiction in the six months prior to the date of signature of the Informed Consent Form; Obstructive biliary disorders; Refractory hypokalemia and/or conditions involving marked potassium loss, hyperkalemia, and/or hyponatremia; History of symptomatic hyperuricemia; History of secondary hypertension; History of cancer, without documentation of remission/cure;